A Randomized, Double Blind, Placebo Controlled, Study to Demostrate the Cognitive Enhancing Effects of BF2.649 in People With Schizophrenia and Schizoaffective Disorder.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2012
At a glance
- Drugs Pitolisant (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 16 Aug 2012 Actual end date (1 Oct 2011) added as reported by ClinicalTrials.gov.
- 24 Jun 2008 New trial record.